Clinical Trials Browser

Phase 2 × Completed × tafasitamab × Clear all

NCT02005289 2025-12-15

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT01685008 2023-11-07

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

Phase 2 Completed

92 enrolled 37 charts

Lymphoma, Non-Hodgkin

NCT02399085 2023-10-23

L-MIND

Phase 2 Completed

81 enrolled 23 charts 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT02639910 2021-12-20

COSMOS

Phase 2 Completed

24 enrolled 13 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell